Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)

NCT01432535 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Insufficiency

Interventions

DRUG: PegIFN-2b (Sylatron®)

Sponsor

Merck Sharp & Dohme LLC